KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EPS (Weighted Average and Diluted) (2019 - 2025)

Moderna (MRNA) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$2.11 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 27.49% to -$2.11 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.27 through Dec 2025, up 21.66% year-over-year, with the annual reading at -$7.26 for FY2025, 21.77% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$2.11 at Moderna, down from -$0.51 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $11.29 in Q4 2021, with the low at -$9.53 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.97, with a median of $0.11 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 2183.87% in 2021, then tumbled 1800.0% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $11.29 in 2021, then plummeted by 67.58% to $3.66 in 2022, then tumbled by 84.7% to $0.56 in 2023, then crashed by 619.64% to -$2.91 in 2024, then increased by 27.49% to -$2.11 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$2.11, -$0.51, and -$2.13 for Q4 2025, Q3 2025, and Q2 2025 respectively.